Primary Biliary Cholangitis
Conditions
Keywords
Saroglitazar Magnesium, Primary Biliary Cholangitis, PBC
Brief summary
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Detailed description
A Multicenter, Randomized, Double-blind, Placebo controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis
Interventions
Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
DRUGPlacebo
Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
Sponsors
Zydus Therapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double-blind Masking
Intervention model description
Multicenter, Randomized, Double-blind, Placebo controlled, Phase 2b/3 Safety and Efficacy Study . Initially, 192 subjects (64 subjects in each treatment arm) were planned be randomised in a ratio of 1:1:1 in Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, and Placebo arm, respectively. After an optimal dose selection, the subjects are randomised in 2:1 ratio of Saroglitazar Magnesium 1 mg or placebo. There would be approximately 140 evaluable subjects (90 of Saroglitazar 1 mg and 50 of placebo arm)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Males or females, between 18 and 75 years of age, both inclusive at screening. 2. Subjects on ursodeoxycholic acid (UDCA) for at least 12 months at a therapeutic dose (at least 13 mg/kg per day) and a stable dose for 6 months prior to Screening Visit and having ALP ≥ 1.67 x ULN. OR Subjects who are unable to tolerate UDCA and did not receive UDCA for at least 3 months prior to the date of screening and having ALP ≥ 1.67 x ULN. 3. History of confirmed PBC diagnosis, based on American Association for the Study of Liver Disease \[AASLD\] and European Association for Study of the Liver \[EASL\] Practice Guidelines, as demonstrated by the presence of at least ≥ 2 of the following 3 diagnostic factors: * History of elevated ALP levels for at least 6 months prior to screening * Positive anti-mitochondrial antibodies (AMA) titer OR positive PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\]) if AMA is negative * Liver biopsy consistent with PBC 4. ALP ≥ 1.67 x ULN at both Visits 1 and 2 and \< 30% variance between the levels from Visit 1 to Visit 2 5. Total bilirubin \< 2 x ULN at screening (Visit 1) 6. Must provide written informed consent and agree to comply with the trial protocol.
Exclusion criteria
1. Consumption of 2 standard alcohol drinks per day if male and 1 standard alcohol drink per day if female for at least 3 consecutive months (12 consecutive weeks) within 5 year before screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor). 2. History or presence of other concomitant liver diseases at screening: 1. Chronic hepatitis B or C virus (HBV, HCV) infection. (Note: However, If the subject has been treated for the HCV infection and has been cured for a duration of more than 2 years from screening, such subjects can be enrolled in the study) 2. Primary sclerosing cholangitis (PSC). 3. Alcoholic liver disease. 4. Autoimmune hepatitis (AIH) indicative of PBC with overlap syndrome. Note: The Paris criteria are commonly used to define the presence of PBC with features of AIH and have been endorsed by EASL and AASLD. According to these criteria, a diagnosis can be made in a patient with PBC as follows: At least two of the following: I. ALP \> 2 x ULN or GGT \> 5 x ULN. II. AMA positive III. Florid bile duct lesion on histology. AND At least two of the following three features: I. ALT \> 5 x ULN. II. Immunoglobulin G serum levels \> 2 x ULN or smooth muscle autoantibody positive. III. Moderate to severe interface hepatitis on histology. e. Hemochromatosis. f. Non-alcoholic steatohepatitis (NASH) on historical biopsy. 3.Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, ascites requiring treatment, encephalopathy, known large esophageal varices or history of variceal bleeding within one year prior to screening or history of hepatorenal syndrome. 5.Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease) or which may diminish life expectancy to \< 2 years, including known cancers. 6.Use of thiazolidinediones or fibrates (within 12 weeks prior to screening). 7.Use of obeticholic acid (OCA), azathioprine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, budesonide and other systemic corticosteroids (Note: Prednisone dose should not be more than 10 mg per day); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin) (within 12 weeks prior to screening). 9.History of bowel surgery (gastrointestinal \[bariatric\] surgery in the preceding 1 year or undergoing evaluation for gastrointestinal surgery (bariatric surgery for obesity, extensive small-bowel resection) or orthotopic liver transplant (OLT) or listed for OLT. 10.Type 1 diabetes mellitus. 11.Unstable cardiovascular disease, including: a. Unstable angina, (i.e., new or worsening symptoms of coronary heart disease in the 12 weeks before screening and throughout the Screening Period), acute coronary syndrome in the 24 weeks before screening and throughout the Screening Period, acute myocardial infarction in the 12 weeks before screening and throughout the Screening Period or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, in the 24 weeks before screening and throughout the Screening Period. b. History/current unstable cardiac dysrhythmias. c. Uncontrolled hypertension at screening. d. Stroke or transient ischemic attack in the 24 weeks before screening. 12.History of intracranial hemorrhage, arteriovenous malformation, bleeding disorder, coagulation disorders, or screening blood tests that, in the opinion of the Investigator, indicate altered coagulability (e.g., PT, INR, aPTT) at screening. 13.An uncontrolled thyroid disorder 1. Uncontrolled hyperthyroidism: defined as any history of hyperthyroidism that has either not been treated with either radioactive iodine and/or surgery or that has been treated with radioactive iodine and/or surgery, but has required ongoing continuous or intermittent use of thyroid hormone synthesis inhibitors (i.e., methimazole or propylthiouracil) in the 24 weeks before screening. 2. Uncontrolled hypothyroidism: defined as initiation of thyroid hormone replacement therapy or dose adjustment of replacement therapy in the 12 weeks before screening. 14.History of myopathies or evidence of active muscle disease demonstrated by CPK ≥ 5 x ULN at screening. 15.For subjects with elevated baseline ALT or AST; ALT or AST exceeding by more than 50% on Visit 2 compared to Visit 1. Note: If the ALT or AST values on Visit 2 exceed by more than 50% from Visit 1, then a third value will be measured (within 1- 2 weeks) to assess for the trend. If the third value shows continued increase ≥ 10%, then subject is considered ineligible for randomization. 16.Any of the following laboratory values at screening: a. Platelets \< 50 × 109/L b. Albumin \< 2.8 g/dL c. eGFR \< 45 mL/min/1.73 m2 d. ALP \> 10 x ULN e. ALT or AST \> 250 U/L 17.Participation in another interventional clinical study and receipt of any other investigational medication (within 12 weeks prior to randomization up to end of study). 18.History of malignancy in the past 5 years and/or active neoplasm with the exception of resolved superficial non-melanoma skin cancer. 19.Contraindications to Saroglitazar Magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar Magnesium. 20.Known allergy, sensitivity, or intolerance to the study drug, comparator, or formulation ingredients. 21.Pregnancy-related exclusions, including: a. Pregnant/lactating female (including positive pregnancy test at screening). b. Pregnancy should be avoided by male and female subjects either by true abstinence or the use of an acceptable effective contraceptive measures for the duration of the study and for at least 1 month after the end of the study treatment. Refer Appendix 8 Contraceptive Guidance 22.History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the Investigator, unsuitable for the study (such as poorly controlled psychiatric disease, HIV, coronary artery disease, or active gastrointestinal conditions that might interfere with drug absorption). 23.Cirrhosis with Child-Pugh-Turcotte (CPT) Class B or C having score of 7 or above at screening 24.Subjects with Model for End Stage Liver Disease (MELD 3.0) score of 12 or above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects with biochemical response based on the composite endpoints of ALP and total bilirubin | From baseline to week 52 | ALP \< 1.67 x ULN, ≥ 15% decrease in ALP relative to baseline, and total bilirubin ≤ ULN or direct bilirubin ≤ ULN in subjects with known Gilbert's syndrome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects with complete normalization of ALP. | From baseline to week 52 | ALP≤ULN |
| Pruritis assessed by 5 D itch scales | From baseline to Week 24 and Week 52 | Change from baseline in 5-D itch score |
| Proportion of subjects with biochemical response based on the composite endpoints of ALP and total bilirubin | From baseline to Weeks 4, 8, 16, and 24. | ALP \< 1.67 x ULN, ≥ 15% decrease in ALP, and total bilirubin ≤ ULN or direct bilirubin ≤ ULN in subjects with known Gilbert's syndrome |
| Proportion of subjects change from baseline in ALP | From baseline to Weeks 24 and 52. | ALP improvement of at least 15%, 30%, 40%, and 50% Absolute and percent change from baseline in ALP values |
| Quality of life assessed by the PBC 40 questionnaire | From baseline to Weeks 16, 24, and 52. | Change from baseline in quality of life (PBC 40) questionnaire domains (total score and domain score) |
| Improvement in liver stiffness measurement (LSM) of at least 25% relative to baseline assessed by Liver elastography/FibroScan® | From baseline to Weeks 24 and Week 52 | Proportion of subjects with a decrease in LSM of at least 25% |
| To effect on liver enzymes | From baseline at Weeks 16, 24, and 52. | Change from baseline in liver enzyme parameters (ALT, AST, GGT, and total bilirubin \[direct and indirect bilirubin\]) |
| The effect on liver enzymes | From baseline to week 24 and week 52 | Change from baseline in serum bile acids |
| The effect on lipid parameters | From baseline to weeks 24 and 52 | Change from baseline in lipid parameters (TG, LDL-C, HDL-C, VLDL-C, total cholesterol, and non-HDL-C) |
Countries
Argentina, Iceland, Turkey (Türkiye), United States
Contacts
STUDY_DIRECTORDeven V Parmar, MD
Zydus Therapeutics Inc.
Outcome results
None listed